Biotech developing a bifunctional EGFR/TGF-beta-trap antibody (ficerafusp alfa) for head-and-neck and other solid tumors.
Biotech developing a bifunctional EGFR/TGF-beta-trap antibody (ficerafusp alfa) for head-and-neck and other solid tumors.
Has no product revenue and funds trials by selling shares, so each data readout and financing round shapes what it can afford to run. Ficerafusp alfa attacks a tumour in two ways, blocking a growth receptor (EGFR) and neutralising a signal (TGF-beta) that helps tumours hide from the immune system, and it is tested alongside a checkpoint-inhibitor drug.
Moat: none (IP / patents). Pre-commercial; differentiation rests on unproven combined EGFR/TGF-beta mechanism data.
Headquarters: Boston, Massachusetts, US · Founded: 2021 · Employees: 103
Size Bicara Therapeutics (BCAX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $623M, the 2530th largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.38 on 18 Nov 2026.
Performance Over six months the shares fell 54.1%, against -19.0% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 20 in its peer set.
Short interest Short interest is 14.9% of the free float (30 Oct 2026).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$191,000 | -$105,000 | -$56,000 | -$19,000 | -$10,000 |
| EBITDA | -$237M | -$155M | -$82.3M | -$39.9M | -$37.6M |
| Net income | -$220M | -$138M | -$68.0M | -$52.0M | -$37.8M |
| Free cash flow | -$163M | -$107M | -$74.8M | -$46.2M | -$32.3M |
| Capital expenditure | $1.02M | $280,000 | $71,000 | $586,000 | $192,000 |
| Total debt | $880,000 | $1.71M | $738,000 | $657,000 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Bicara Therapeutics BCAX | $623M | -54% | n/a | n/a | n/a | n/a |
| Merck & MRK | $340B | +23% | +5% | 18% | 5.7× | 8.3% |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 7.3× | 11.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BCAX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -48.9% | -10.2% | lowest of 20 |
| 6-month return | -54.1% | -19.0% | lowest of 20 |
| Distance from 52-week high | -69.7% | -38.0% | 2nd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | 5.3× | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | 1.6× | n/a | n/a |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 3.0× | -8.7% | +8.8% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | 16.9× | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 6.1× | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | 2.4× | 10.9% | -5.9% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | 3.3× | 10.1% | +2.1% |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 25.1× | 9.1% | -25.1% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | 2.0× | -1.0% | -17.9% |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 0.5× | -6.6% | +5.4% |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | 12.8× | 36.3% | +16.2% |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 3.0× | 9.1% | +7.9% |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | 10.6× | n/a | n/a |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | 1.2× | -0.6% | -1.6% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 7.5× | n/a | n/a |
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 3.4× | 27.1% | +31.4% |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 0.9× | -6.2% | +6.5% |